drugset / Trial / NCT02465138

A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis

NCT02465138

RandomizedParallel-groupDouble-blindPrevention

Summary

Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis. Determine if IV ketorolac provides improved post-procedure analgesia. Determine if systemic mediators of inflammation are reduced in patients receiving IV ketorolac following ERCP.

Timeline

Start
2023-11
Primary completion
2025-12
Completion
2026-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Other / unclassified Intravenous

Indications